Clinical significance and prognostic value of STAT3 expression in patients with diffuse large B-cell lymphoma treated with rituximab-CHOP therapy

被引：0
|
作者：
Liu, Hui [1 ,2 ]
Zhu, Li [1 ,2 ]
Sun, Caihong [2 ,3 ]
Xie, Wanzhuo [1 ,2 ]
Qian, Wenbin [1 ,2 ]
Ye, Xiujin [1 ,2 ]
机构：
[1] Zhejiang Univ, Affiliated Hosp 1, Dept Hematol, Key Lab Hematopoiet Malignancies, 79 Qingchun Rd, Hangzhou 310003, Zhejiang, Peoples R China
[2] Zhejiang Univ, Affiliated Hosp 1, Inst Hematol, 79 Qingchun Rd, Hangzhou 310003, Zhejiang, Peoples R China
[3] Zhejiang Univ, Affiliated Hosp 1, Dept Hematol, Hangzhou 310003, Zhejiang, Peoples R China
来源：
INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE | 2016年 / 9卷 / 06期
基金：
中国国家自然科学基金;
关键词：
Diffuse large B-cell lymphoma; immunophenotype; STAT3; signaling pathway; survival; INDEX NCCN-IPI; TISSUE MICROARRAY; CHEMOTHERAPY; CLASSIFICATION; VALIDATION; ACTIVATION; SURVIVAL; IL-6; ERA;
D O I：
暂无
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
The clinical significance and prognostic value of Signal transducer and activator of transcription 3 (STAT3) were investigated in a cohort (n = 52) of patients with diffuse large B-cell lymphoma (DLBCL) treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP), by immunohistochemical (IHC) analysis in this study. High STAT3 expression was detected in 65.38% (34/52) cases. Compared with germinal center B-cell (GCB) group, the non-GCB group had significantly higher STAT3 expression rate (82.61% versus 51.72%, P = 0.02). Our data also suggest that high STAT3 expression level correlated with poor survival in DLBCL patients with respect to both 5-year OS (72.2% versus 41.2%, P = 0.033) and PFS (66.7% versus 32.4%, P = 0.023). The results of this study provide evidence for the ongoing researches targeting STAT3 in DLBCL.
引用
收藏
页码：9356 / 9364
页数：9
相关论文
共 50 条
  • [1] Prognostic and biological significance of survivin expression in patients with diffuse large B-cell lymphoma treated with rituximab-CHOP therapy
    Liu, Zhiyu
    Xu-Monette, Zijun Y.
    Cao, Xin
    Manyam, Ganiraju C.
    Wang, Xiaoxiao
    Tzankov, Alexandar
    Xia, Yi
    Li, Xin
    Visco, Carlo
    Sun, Ruifang
    Zhang, Li
    Montes-Moreno, Santiago
    Dybkaer, Karen
    Chiu, April
    Orazi, Attilio
    Zu, Youli
    Bhagat, Govind
    Richards, Kristy L.
    Hsi, Eric D.
    Choi, William W. L.
    van Krieken, J. Han
    Huh, Jooryung
    Ponzoni, Maurilio
    Ferreri, Andres J. M.
    Parsons, Ben M.
    Moller, Michael B.
    Piris, Miguel A.
    Winter, Jane N.
    O'Malley, Dennis P.
    Medeiros, L. Jeffrey
    Young, Ken H.
    [J]. MODERN PATHOLOGY, 2015, 28 (10) : 1297 - 1314
  • [2] Prognostic Significance of Survivin Expression in Patients with Diffuse Large B-Cell Lymphoma Treated with R-CHOP Therapy: A Report from the International DLBCL Rituximab-CHOP Consortium Program
    Liu, Zhiyu
    Xu-Monette, Zijun Y.
    Cao, Xin
    Visco, Carlo
    Tzankov, Alexander
    Montes-Moreno, Santiago
    Dybkaer, Karen
    Chiu, April
    Orazi, Attilio
    Zu, Youli
    Bhagat, Govind
    Richards, Kristy L.
    Hsi, Eric D.
    Choi, William W. L.
    van Krieken, J. Han
    Huh, Jooryung
    Ai, Weiyun
    Ponzoni, Maurilio
    Ferreri, Andres J. M.
    Farnen, John P.
    Moller, Michael B.
    Winter, Jane N.
    Piris, Miguel A.
    Medeiros, L. Jeffrey
    Young, Ken H.
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2015, 15 : S216 - S216
  • [3] Prognostic Significance of Survivin and Caspase-3 Immunohistochemical Expression in Patients with Diffuse Large B-cell Lymphoma Treated with Rituximab and CHOP
    Mitrovic, Zdravko
    Ilic, Ivana
    Aurer, Igor
    Kinda, Sandra Basic
    Radman, Ivo
    Dotlic, Snjezana
    Ajdukovic, Radmila
    Labar, Boris
    [J]. PATHOLOGY & ONCOLOGY RESEARCH, 2011, 17 (02) : 243 - 247
  • [4] STAT3 Expression and Clinical Implications In De Novo Diffuse Large B-Cell Lymphoma: A Report Fro The International DLBCL Rituximab-CHOP Consortium Program
    Ok, Chi Young
    Xu-Monette, Zijun Y.
    Tzankov, Alexander
    Visco, Carlo
    Montes, Santiago M.
    Dybkaer, Karen
    Chiu, April
    Orazi, Attilio
    Zu, Youli
    Bhagat, Govind
    Richards, Kristy L.
    Hsi, Eric D.
    Choi, William W. L.
    Van Krieken, Joannes H. J. M.
    Huang, Qin
    Huh, Jooryung
    Ai, Weiyun Z.
    Ponzoni, Maurilio
    Ferreri, AndrEs J. M.
    Farnen, John P.
    Moller, Michael B.
    Winter, Jane N.
    Piris, Miguel A.
    Medeiros, L. Jeffrey
    Young, Ken H.
    [J]. BLOOD, 2013, 122 (21)
  • [5] Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma
    Habermann, Thomas M.
    Weller, Edie A.
    Morrison, Vicki A.
    Gascoyne, Randy D.
    Cassileth, Peter A.
    Cohn, Jeffrey B.
    Dakhil, Shaker R.
    Woda, Bruce
    Fisher, Richard I.
    Peterson, Bruce A.
    Horning, Sandra J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (19) : 3121 - 3127
  • [6] Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma
    Habermann, T
    Weller, E
    Morrison, V
    Gascoyne, R
    Cassileth, P
    Cohn, J
    Dakhil, S
    Woda, B
    Fisher, R
    Peterson, B
    Horning, S
    [J]. ANNALS OF ONCOLOGY, 2005, 16 : 103 - 103
  • [7] PROGNOSTIC SIGNIFICANCE OF SARCOPENIA IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA TREATED WITH RITUXIMAB PLUS CHOP (R-CHOP)
    Go, S. I.
    Park, M. J.
    Kim, H. G.
    Kang, M. H.
    Lee, G. W.
    [J]. HAEMATOLOGICA, 2016, 101 : 686 - 687
  • [8] PROGNOSTIC FACTORS AND OUTCOMES IN PRIMARY DIFFUSE LARGE B-CELL LYMPHOMA OF ADRENAL GLAND TREATED WITH RITUXIMAB-CHOP CHEMOTHERAPY
    Hyun, S. Y.
    Kim, Y. R.
    Eun, J. Ji
    Kim, J. S.
    Yoon, D. H.
    Suh, C. W.
    Shin, H. J.
    Mun, Y. C.
    Park, Y.
    Do, Y. R.
    Jeong, S. H.
    Park, J. S.
    Park, E. K.
    Jang, J. S.
    Lee, W. S.
    Lee, H. W.
    Eom, H. S.
    Ahn, J. S.
    Jeong, J. H.
    Baek, S. K.
    Kim, S. J.
    Kim, W. S.
    [J]. HAEMATOLOGICA, 2012, 97 : 659 - 659
  • [9] Effect of Nutritional Status on Survival Outcome of Diffuse Large B-Cell Lymphoma Patients Treated with Rituximab-CHOP
    Park, Silvia
    Han, Boram
    Cho, Jae Won
    Woo, Sook-young
    Kim, Seonwoo
    Kim, Seok Jin
    Kim, Won Seog
    [J]. NUTRITION AND CANCER-AN INTERNATIONAL JOURNAL, 2014, 66 (02): : 225 - 233
  • [10] CD99 expression and newly diagnosed diffuse large B-cell lymphoma treated with rituximab-CHOP immunochemotherapy
    Junshik Hong
    Sanghui Park
    Jinny Park
    Seung Jun Jang
    Hee Kyung Ahn
    Sun Jin Sym
    Eun Kyung Cho
    Dong Bok Shin
    Jae Hoon Lee
    [J]. Annals of Hematology, 2012, 91 : 1897 - 1906
12345